INDEX

A
AbioCor TAH, 172
Abiomed BVS 5000, 162, 163–165, 164f, 175
advantages of, 164
disadvantages of, 164–165
ACC
guidelines for CABG patients with poor LV function, 58t
radionuclide techniques myocardium assessment, 57t
ACE inhibitor therapy, 2
Acorn cardiac support device, 197–198, 197f
Acorn jacket randomized trial, 234f
Acute myocardial infarction (AMI), 156
Acute vascular rejection xenotransplantation, 259–262
Adult extracorporeal membrane oxygenation, 165–167
AHA
guidelines for CABG patients with poor LV function, 58t
radionuclide techniques myocardium assessment, 57t
Alcohol ablation septal
HCM, 218–221
Allotransplantation cardiac
recent advances in, 1–29
American College of Cardiology (ACC)
guidelines for CABG patients with poor LV function, 58t
radionuclide techniques myocardium assessment, 57t
American Heart Association (AHA)
guidelines for CABG patients with poor LV function, 58t
radionuclide techniques myocardium assessment, 57t
American Society of Nuclear Cardiology (ASNC)
radionuclide techniques myocardium assessment, 57t
AMI, 156
Amiodarone for HCM, 207
Aneurysm anteroseptoapical, 283f
CMR assessment of, 289f
Angina complicating LVAD, 159
with HCM, 205
Angiotensin-converting enzyme (ACE) inhibitor therapy, 2
Annuloplasty De Vega, 106f
Kay, 106f
modified De Vega, 105f
ring, 105
Annulus, 99
ANP, 103f
Anterior leaflet, 98
Anteroseptoapical aneurysm, 283f
Anti-αGal antibodies, 249, 251–254
Antiarrhythmic drugs for HCM, 207
Antibodies anti-αGal, 249, 251–254
antilymphocyte, 21–23
preformed natural xenotransplantation, 246–250
Antilymphocyte antibody therapy, 21–23

317
Antiproliferative agents, 19–20
Aortic pseudostenosis, 73f
Aortic stenosis, 68–69
Aortic valve
replacement
  selection for, 71–72
  surgery, 75
resistance, 72–73
surgery
  with left ventricular dysfunction, 67–76
Arrhythmias
  complicating LVAD, 159
Artificial hearts. See Total artificial hearts (TAH)
ASNC
  radionuclide techniques
    myocardium assessment, 57t
Asynergic ventricles
  large, 285–287
Atrial appendage, 98
Atrial fibrillation
  efficacy in, 145–148
  His bundle pacing, 129
  pacing, 128–129
  PAVE trial, 145–146
Atrial natriuretic peptide (ANP), 103f
Atrial vestibule, 98
Atrioventricular node, 98
Atrium
  right, 98
Autologous tissue
  vs synthetic patch, 284
Axial flow pumps
  LVAD, 173–174
Azathioprine, 19, 27
B
Bailey, Charles, 192, 244
Balloon pump
  intra-aortic, 167–168
Balloon sizing, 283f
Basiliximab, 22
Batista, Randas, 192
B-cell tolerance
  xenotransplantation, 258–259
Beck, Claude, 192
Benign polyclonal lymphoproliferation, 28
Berlin heart, 167
β-blockade, 2–3
  for HCM, 207
Bicaval technique, 16
Biphasic response, 48
Biventricular (BV) pacing
  future indications, 149
Biventricular (BV) systems
  history of implantation with, 132–140
Brain death
  cardiac donor, 10
  causing myocardial injury, 11
Branch vein LV lead implantation
  coronary sinus, 138–139
Bundle of His, 98
BV pacing
  future indications, 149
BV systems
  history of implantation with, 132–140
C
CABG
  in patients with poor LV function
    ACC/AHA guidelines for, 58t
Calcineurin inhibitors, 18–19
Calcium channel blockers
  for HCM, 207
Candidate
  heart transplantation, 2–7
Carcinoid tricuspid valve disease, 116–118
Cardiac allograft vasculopathy (CAV), 25–27
Cardiac allotransplantation
  recent advances in, 1–29
Cardiac compression devices
  LVAD, 174–175
Cardiac donor, 10–14
  brain dead, 10
Cardiac magnetic resonance imaging (MRI), 49
Cardiac Resynchronization for Heart Failure (CARE-HF) trial, 145
Cardiac Transplant Research Database (CTRD), 4
Cardiomyopathy idiopathic dilated
  left ventricular volume reduction surgery, 191–200
Cardiomyoplasty-Skeletal Muscle Assist Randomized Trial (C-SMART)
DCMP, 230–231
Cardioplegia solution, 15
CardioWest implantation, 303–304, 303t, 304f
CardioWest total artificial heart, 173f
CARE-HF trial, 145
Carpentier ring annuloplasty, 107f
CASS, 40–42
CAV, 25–27
Cellular rejection
  xenotransplantation, 262–266
Centrifugal Biomedical Biopump, 163f
Centrifugal pumps
  LVAD, 161–167
CHF. See Congestive heart failure (CHF)
Chimerism mixed, 262–265
  molecular
    xenotransplantation, 265
Chordal preservation, 86
Chronic resynchronization therapy (CRT)
  QOL, 146f–147f
Circular patch plasty
  endoventricular, 282–284
Cloning
  xenotransplantation, 257–258
CMV, 24–25
Cohn’s technique, 104
Commissurotomy, 105
COMPANION, 144–145
  Steering Committee Implant Guidelines, 138–139
  trial, 148f
Comparison of Medical Therapy Pacing and Defibrillation in Chronic Heart Failure (COMPANION), 144–145
  Steering Committee Implant Guidelines, 138–139
  trial, 148f
Complement activation xenotransplantation, 250
Conduction delay intraventricular, 124
Congestive heart failure (CHF) REMATCH study, 179, 196, 196f
TAH, 301–314
VENTAK, 143–144
VIGOR, 132, 133t, 141–142
CONSENSUS trial, 2
CONTAK CD, 143–144
CONTAK-CD, 132, 133t
Continuous perfusion donor heart, 15
Contractile function resynchronization therapy, 131–132
Cooley, Denton, 192
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) trial, 2
COPERNICUS, 2
CorCap, 232f
Coronary artery bypass graft (CABG)
  in patients with poor LV function
    ACC/AHA guidelines for, 58t
Coronary artery disease preexisting complicating LVAD, 159
Coronary artery myocardial bridges unroofing, 213
Coronary artery revascularization left ventricular function, 51t
Coronary Artery Surgery Study (CASS), 40–42
Coronary bypass surgery heart failure, 40–43
randomized trials, 40–42
retropective studies, 42–43
Coronary sinus, 98
branch vein LV lead implantation, 138–139
occlusive venography, 134, 134f
Coronary sinus leads, 137f
Corticosteroids, 21
Crista terminalis, 98
CRT
  QOL, 146f–147f
C-SMART
  DCMP, 230–231
CTRD, 4
Curvature restoration, 283f
Cushing reflex, 11
Cyclosporine, 19, 22
Cytomegalovirus (CMV), 24–25

D
Daclizumab, 22
DAVID trial, 130
DCMP, 225–234, 232f
clinical experience with, 226–229
LVEF, 227
operative mortality, 227
passive girdling, 229–230
DeBakey VAD, 174
Defibrillators
  COMPANION, 144–145
  Steering Committee Implant Guidelines, 138–139
trial, 148f
implantable
  for HCM, 208
De Vega annuloplasty, 106f
modified, 105f
Diabetes insipidus, 11
Dilated cardiomyopathy
  idiopathic
    left ventricular volume reduction surgery, 191–200
    early results, 193–194
    future roles, 196–200
    present status, 195–196
  standard dual-chamber pacing, 126–128
Dobutamine, 17
Dobutamine stress
  echocardiography
    low dose, 48
Dobutamine stress echocardiography (DSE), 48
Donor
  cardiac, 10–14
    brain dead, 10
  characteristics, 13
  ideal, 12
  marginal, 13
  optimal assessment, 12t
  optimal management, 14t
  problems, 13
Donor heart
  continuous perfusion, 15
  implantation, 15–16
DSE, 48
Dual chamber pacing
  indications, 127–128
  potential mechanisms, 127
Dynamic cardiomyoplasty
  (DCMP), 225–234, 232f
clinical experience with, 226–229
LVEF, 227
operative mortality, 227
passive girdling, 229–230
Dyspnea
  with HCM, 205
E
Echocardiography
  dobutamine stress, 48
  low-dose dobutamine stress, 48
ECMO, 162
   adult, 165–167
ECSS, 40–42
Ejection fraction, 69f
Enalapril
   CONSENSUS trial, 2
Endocarditis
   tricuspid valve, 111–112
Endoventricular circular patch
   plasty (EVCPP), 282–284
Endoventricular patch reconstruction, 283f
Endoventricular purse string suture, 283f
European Cooperative Coronary
   Study (ECSS), 40–42
EVCPP, 282–284
Everolimus, 20
Extracorporeal membrane oxygenation (ECMO), 162
   adult, 165–167
F
Fatigue
   with HCM, 205
FK506-binding protein (FKBP), 20
Fossa ovalis, 98
G
Geometrical mitral reconstruction
   bicaval cannulation, 91f
   heart failure, 88–92
Heart. See also Total artificial
   hearts (TAH)
   right
   anatomy, 98–101
   view from right side, 210f
Heart failure
   CARE-HF trial, 145
   coronary bypass surgery, 40–43
   randomized trials, 40–42
   geometrical mitral reconstruction, 88–92
   ischemic
      left ventricular reconstruction, 279–297
   ischemic heart disease, 43–44
   mechanical revascularization
      future of, 56–59
      mitral valve alterations, 80–82
      mitral valve replacement, 85–88
      pacing, 123–149
   right, 108–118
      tricuspid valve surgery, 97–118
   surgical revascularization, 51–54
   quality of life, 52
   survival, 52–54
   symptoms, 51–52
Heart Failure Survival Score, 3
HeartMate II, 174
Heart transplantation
   candidate, 2–7
   contraindications, 4t
   CTRD, 4
   for HCM, 208
   pigs, 246f
   priorities, 8t
   recipient
      infection, 24–25
      malignancy, 27–28
      waiting list, 7–10
Hemodynamic instability, 13
Hibernating myocardium, 43
His bundle pacing
   atrial fibrillation, 129
Human immunodeficiency virus
   (HIV), 6
Humoral rejection, 23–24
Hyperacute rejection, 6
   xenotransplantation, 245–259,
   251–252
Hypertrophic cardiomyopathy (HCM)
   amiodarone, 207
   angina with, 205
   antiarrhythmic drugs, 207
Index

β-blockade, 207
calcium channel blockers, 207
classification of, 204
clinical presentation of, 204–206
dyspnea with, 205
fatigue with, 205
heart transplantation, 208
hemodynamic characteristics of, 205
obstructive physiology of, 206–207
prevalence of, 204
septal alcohol ablation, 218–221
surgery of, 203–221
treatment, 207–221
medical, 207–208

I
IABP, 167–168
Ideal donor, 12
Idiopathic dilated cardiomyopathy
   left ventricular volume reduction surgery, 191–200
   early results, 193–194
   future roles, 196–200
   present status, 195–196
Immediate posttransplant course, 16–18
Immunosuppression, 18–23
Implantable defibrillators
   for HCM, 208
Implantation
donor heart, 15–16
Induction therapy, 21–23
Infection
   complicating LVAD, 160
   heart transplantation recipient, 24–25
Infectious disease
   xenotransplantation, 266
InSYnc Trial, 143
International Society for Heart and Lung Transplantation (ISHLT) Registry, 1, 20
cyclosporine and tacrolimus, 19
hepatitis B and hepatitis C, 5
pulmonary hypertension, 4
Intra-aortic balloon pump (IABP), 167–168
Intracorporeal pumps
   LVAD, 167–170
Intraoperative postmyectomy transesophageal echocardiography, 213
Intravascular ultrasound (IVUS), 25–26
Intraventricular conduction delay (IVCD), 124
Ischemic heart disease
   heart failure, 43–44
   Ischemic heart failure
      left ventricular reconstruction, 279–297
      STITCH study, 56–58
IVCD, 124
IVUS, 25–26
J
Jarvik 2000, 174
K
Kay annuloplasty, 106f
Kay-Wooler repair, 104
L
Laplace’s law, 192
Large akinetic segments, 285, 286f
Large asynergic ventricles, 285–287
Latissimus dorsi muscle, 227
LDSE, 48
Leads
   branch vein LV
      coronary sinus, 138–139
   coronary sinus, 137f
   over the wire, 136
   transvenous coronary sinus pacing, 136
Left ventricular assist devices (LVAD), 155–180
angina complicating, 159
axial flow pumps, 173-174
cardiac compression devices, 174-175
centrifugal pumps, 161-167
device selection, 175-178
indications for, 156-157
infection complicating, 160
intracorporeal pumps, 167-170
patient selection, 157-161, 158t
cardiac factors, 158-160
noncardiac factors, 160-161
postoperative management, 178-180
destination therapy, 179-180
early, 178-179
explant vs transplant, 179
late, 179
pumps, 161-175
risk factors for poor survival, 162t
Left ventricular dysfunction
aortic valve surgery with, 67-76
diagnosis of, 73-74
mitral valve surgery, 79-92
Left ventricular ejection fraction (LVEF)
DCMP, 227
Left ventricular end diastolic pressure (LVEDP), 101
Left ventricular function coronary artery
revascularization, 51t
Left ventricular outflow tract (LVOT), 87
Left ventricular pacing, 148-149
Left ventricular reconstruction, 283f
ischemic heart failure, 279-297
actuarial survival curves, 296f
circular reorganization of left ventricle, 282-287
clinical characteristics, 294t
disappointing results, 291-293
future, 293-294
large asynergic ventricles, 285-287
late survival, 292-293
results, 287-290
revascularization, 281
surgery, 281-282
Left ventricular (LV) syndrome, 101
Left ventricular volume reduction surgery
idiopathic dilated cardiomyopathy, 191-200
eyearly results, 193-194
future roles, 196-200
present status, 195-196
Liotta heart, 301
Low-dose dobutamine stress echocardiography (LDSE), 48
LVAD. See Left ventricular assist devices (LVAD)
LVEDP, 101
LVEF
DCMP, 227
LVOT, 87
LV syndrome, 101
Lymphoma
monoclonal malignant, 28
M
Magnetic resonance imaging (MRI)
cardiac, 49
Malignancy
heart transplantation recipient, 27-28
Malignant lymphoma
monoclonal, 28
Marginal donor, 13
Means systolic aortic pressure gradients, 70f
Milrinone, 17
MIRACLE trial, 132, 143
Mitral insufficiency, 284
Mitral reconstruction geometrical
bicaval cannulation, 91f
heart failure, 88-92
Mitral regurgitation classification, 81
Mitral stenosis complicating LVAD, 159
Mitral valve, 104
alterations
heart failure, 80–82
surgery
with left ventricular dysfunction, 79–92
preoperative preparation, 82–83
Mitral valve replacement (MVR)
heart failure, 85–88
Mixed chimerism, 262–265, 264f
Modified De Vega annuloplasty, 105f
Molecular chimerism xenotransplantation, 265
Monoclonal malignant lymphoma, 28
MVR
heart failure, 85–88
Myectomy. See Surgical myectomy
Myocardial viability assessment of, 44–51
detection, 49–51
dobutamine echocardiography, 47–49
DSE, 84
FDG, 84
MRI, 84
PET, 44–45, 84
technetium-99 perfusion imaging, 47
thallium perfusion imaging, 45–47, 46f
Myocardium
hibernating, 43
Myocor Myosplint, 233
Myosplint, 198–200, 199f
N
NF-KB
preventing acute vascular rejection in xenotransplantation, 260–261
Nitroprusside, 72
Novacor N1000PC, 170–171, 171f, 175
Nuclear factor-KB (NF-KB)
preventing acute vascular rejection in xenotransplantation, 260–261
Nuclear transfer xenotransplantation, 257–258
O
Obstructive hypertrophic cardiomyopathy
physiology of, 206–207
Occlusive venography
coronary sinus, 134, 134f
OPO, 9
Optimal donor management, 14t
Organ donor. See Donor
Organ procurement organization (OPO), 9
Organ recipient. See Recipient
Over the wire leads, 136
P
Pacemakers
for HCM, 208
role, 125–126
technology evolution, 134–147
Pacing
atrial fibrillation, 128–129
BV
future indications, 149
COMPANION, 144–145
Steering Committee Implant Guidelines, 138–139
trial, 148f
heart failure, 123–149
His bundle
atrial fibrillation, 129
PAVE trial, 145–146
standard dual-chamber
dilated cardiomyopathy, 126–128
Pacing for Cardiomyopathies (PACMAN), 145
PACMAN, 145
Palpitations
with HCM, 205–206
Partial left ventriculectomy, 193–194, 193f
Passive girdling
DCMP, 229–230
Patch reconstruction
endoventricular, 283f
PATH-CHF, 132
Patients with Chronic Atrial Fibrillation and Ventricular-Based Pacing (PAVE) trial, 145–146
PAVE trial, 145–146
PCCS, 156
PERV, 266
Pigs
heart transplantation, 246f
transgenic, 255f, 259–260
as xenotransplantation donors, 242
Polyclonal B-cell proliferation, 28
Polyester jacket, 232f
Polytetrafluoroethylene (PTFE), 87
Poor left ventricular function
ACC/AHA guidelines for CABG, 58t
Porcine endogenous retroviruses (PERV), 266
Postcardiotomy cardiogenic shock (PCCS), 156
Posterior leaflet, 98
Posttransplant clinical course, 23–28
rejection, 23–24
Posttransplant course immediate, 16–18
Posttransplant lymphoproliferative disorder (PTLD), 27–38
Prednisone, 22
Preexisting coronary artery disease complicating LVAD, 159
Preformed natural antibodies xenotransplantation, 246–250
Presyncope
with HCM, 206
Progressive global ventricular hypokinesia, 280
Protective genes preventing acute vascular rejection in xenotransplantation, 260–261
Pseudostenosis aortic, 73f
PTFE, 87
PTLD, 27–38
Pulmonary vascular resistance (PVR), 101
Pumps LVAD, 161–175
Purse string suture endoventricular, 283f
PVR, 101
Q
Quality of life (QOL)
CRT, 146f–147f
TAH, 313–314
R
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) study, 179, 196, 196f
Rapamycin, 20
Recipient
  heart transplantation
    infection, 24–25
    malignancy, 27–28
Reemtsma, Keith, 243
Regurgitation
  mitral
    classification, 81t
  tricuspid, 109
Rejection
  humoral, 23–24
  hyperacute, 6
  vascular, 23–24
xenotransplantation
  acute vascular, 259–262
  cellular, 262–266
  hyperacute, 245–259, 251–252
RE-LE-VENT, 145
REMATCH study, 179, 196, 196f
Remodeling of Cardiac Cavities by
  Long Term Left Ventricular Based Pacing in Patients with
  Severe Heart Failure (RE-LE-VENT), 145
Renal failure
  complicating LVAD, 160
RESTORE, 195
Resynchronization devices
  clinical trials, 140–149, 141f
  current trials, 141–145
  end points, 142f
  long-term issues, 139–140
Resynchronization therapy, 129–149
  defined, 129
  potential mechanisms, 131–132
  rationale, 129–131
  surgical issues, 132–140
Retroviruses
  porcine endogenous, 266
Revascularization, 50–51, 284
Reverse remodeling
  resynchronization therapy, 132
Rheumatic, 113–114
Right atrium, 98
Right heart
  anatomy, 98–101
Right heart failure, 108–118
  tricuspid valve surgery, 97–118
Right-sided failure
  pathophysiology, 101–102
Right ventricle, 99–100, 100f
  function, 17
Ring annuloplasty, 105
S
SAM
  of mitral valve, 211f
Septal alcohol ablation
  HCM, 218–221
Septal annulus, 98
Septal leaflet, 98
Shumway technique, 15
Sinus venarium, 98
Sirolimus, 20
Standard dual-chamber pacing
  dilated cardiomyopathy, 126–128
Stenosis
  aortic, 68–69
  mitral
    complicating LVAD, 159
  tricuspid, 110–111
STITCH study, 56–58
Stress echocardiography
  dobutamine, 48
  low-dose dobutamine, 48
Sudden death
  with HCM, 206
Sulcus terminalis, 98
Suppressing complement activation
xenotransplantation, 254
Surgical myectomy
  for HCM, 208–218
    operative technique, 209–213
    postoperative management, 213–214
    preoperative assessment, 209
    results, 214–218
    TEE, 213
Surgical Treatment for Ischemic Heart Failure (STITCH) study, 56–58
Surgical ventricular restoration (SVR), 58
Survival ventricular remodeling, 55–56
SVR, 58
Swine
heart transplantation, 246f
transgenic, 255f, 259–260
as xenotransplantation donors, 242
Syncope
with HCM, 206
Systolic anterior motion (SAM) of mitral valve, 211f
Systolic dysfunction causes of, 68–71
T
Tacrolimus, 19
TAH. See Total artificial hearts (TAH)
Target of rapamycin (TOR) inhibitors, 20
TCI Heart-Mate Implantable Pneumatic, 175
TCI Heart-Mate Vented Electric, 175
TEE
intraoperative postmyectomy, 213
Tendon of Todaro, 98
Thoratec HeartMate, 168–170, 169f, 175
Thoratec VAD, 165, 166f
Thymic transplantation xenotransplantation, 265–266
TOR inhibitors, 20
Total artificial hearts (TAH), 155, 172–175
CardioWest, 173f
CHF, 301–314
description, 304–305
device management, 310–312
future, 313–314
implantation, 306–310
indications, 305–306
patient condition, 310–312
QOL, 313–314
survival, 313–314
world experience with, 302t, 303t
Transesophageal echocardiography (TEE)
intraoperative postmyectomy, 213
Transgenic swine, 255f, 259–260
Transplant operation, 15–16
Transvenous coronary sinus pacing leads, 136
Triangle of Koch, 98
Tricuspid regurgitation, 109
after heart transplantation, 112–113
Tricuspid stenosis, 110–111
Tricuspid valve, 98, 104
anatomy, 98–101
carcinoid disease, 116–118
endocarditis, 111–112
surgery, 102–108
causes, 109t
indications, 109t
right heart failure, 97–118
Tricuspid valve disease following mitral valve surgery, 114–116
secondary causes, 110t
Type I endothelial cell activation xenotransplantation, 250–251
U
United Network for Organ Sharing (UNOS), 2
Unroofing
coronary artery myocardial bridges, 213
V
VACS, 40–42
VAD, 155, 176t–177t
Vascular rejection, 23–24
  acute xenotransplantation, 259–262
Vasoconstrictor vasopressin, 18
Venography
  occlusive coronary sinus, 134, 134f
VENTAK CHF/CONTAK CD, 143–144
Ventricles
  large asynergic, 285–287
  right, 99–100, 100f function, 17
Ventricular assist devices (VAD), 155, 176t–177t
Ventricular dyssynchrony, 124–125
Ventricular wall
  after infarction, 280–281
Ventriculectomy
  partial left, 193–194, 193f
Ventriculography, 288f
Verapamil
  for HCM, 207
Vestibule, 98
Veterans Administration Cooperative Study (VACS), 40–42
VIGOR-CHF, 132, 133t, 141–142

W
Waiting list
  heart transplantation, 7–10
Wooler annuloplasty, 106f
Wythenshawe technique, 16

X
Xenotransplantation, 239–267
  acute vascular rejection, 259–260, 259–262
  advantages of, 240–241
  animal donors, 241–243
  B-cell tolerance, 258–259
  cellular rejection, 262–266
  cloning, 257–258
  complement activation, 250
  genetic engineering, 254–257
  history of, 243–244
  hyperacute rejection, 245–259, 251–252
  immunological obstacles, 245–266
  infectious disease, 266
  molecular chimerism, 265
  nuclear transfer, 257–258
  preformed natural antibodies, 246–250
  suppressing complement activation, 254
  thymic transplantation, 265–266
  type I endothelial cell activation, 250–251
  type II endothelial cell activation, 259–260